Skyrizi

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial
AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial
BioSpace
AbbVie
Skyrizi
JNJ
Stelara
Crohn's Disease
clinical trials
Flag link:
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis
Flag link:
AbbVie's Skyrizi posts ulcerative colitis win in maintenance study, teeing up FDA nod
AbbVie's Skyrizi posts ulcerative colitis win in maintenance study, teeing up FDA nod
Fierce Pharma
AbbVie
ulcerative colitis
Skyrizi
FDA
Flag link:
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
Fierce Biotech
AstraZeneca
IBD
AbbVie
JNJ
brazikumab
Skyrizi
Stelara
Flag link:
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Motley Fool
Skyrizi
AbbVie
clinical trials
ulcerative colitis
Flag link:
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
BioSpace
AbbVie
Skyrizi
ulcerative colitis
lupus
Rinvoq
clinical trials
Flag link:
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
AbbVie
Skyrizi
IBD
ulcerative colitis
clinical trials
Flag link:
AbbVie’s Skyrizi hits the spot in refractory psoriasis
AbbVie’s Skyrizi hits the spot in refractory psoriasis
Pharmaphorum
AbbVie
Skyrizi
psoriasis
Flag link:
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
television ads
pharma marketing
DTC ads
AbbVie
Rinvoq
Dupixent
Sanofi
Regeneron
Skyrizi
Novo Nordisk
Ozempic
Jardiance
Eli Lilly
Boehringer Ingelheim
Rybelsus
Trulicity
Rexulti
Otsuka
Lundbeck
Tremfya
JNJ
Verzenio
Flag link:
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
BioPharma Dive
JPMHC 2023
AbbVie
Richard Gonzalez
Pharma CEOs
Humira
Skyrizi
Rinvoq
Flag link:
BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
PR Newswire
Bristol Myers Squibb
AbbVie
Zeposia
Skyrizi
ulcerative colitis
Crohn's Disease
gastroentrologists
Flag link:
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
BioSpace
AbbVie
cedirogant
Skyrizi
Rinvoq
Humira
Flag link:
Where Will AbbVie Be in 3 Years?
Where Will AbbVie Be in 3 Years?
Motley Fool
AbbVie
Humira
biosimilars
Rinvoq
Skyrizi
Vraylar
Flag link:
Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi
Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi
Endpoints
AbbVie
Skyrizi
FDA
Crohn’s disease
Flag link:
Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart
Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart
BioSpace
JNJ
Janssen
Tremfya
Skyrizi
AbbVie
anti-inflammatories
Flag link:
AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?
AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?
Motley Fool
AbbVie
Skyrizi
FDA
psoriatic arthritis
Flag link:
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
AbbVie
earnings
Rick Gonzalez
Skyrizi
Rinvoq
Flag link:
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
Yahoo/Zacks.com
AbbVie
Skyrizi
FDA
psoriatic arthritis
Flag link:
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
AbbVie
Rinvoq
Skyrizi
JPMHC 2022
Flag link:
What AbbVie's Recent Drug News Means for Shareholders
What AbbVie's Recent Drug News Means for Shareholders
Motley Fool
AbbVie
Skyrizi
Crohn’s disease
Europe
Flag link:

Pages